Get the Stockscreener App
18.02
0.08%
0.015
Maplight Therapeutics Inc stock is traded at $18.02, with a volume of 197.54K.
It is up +0.08% in the last 24 hours and up +7.29% over the past month.
MapLight Therapeutics Inc is a biopharmaceutical company. The company is focused on improving the lives of patients suffering from debilitating central nervous system, or CNS, disorders. The company is engaged in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies available for patients. The product candidates of the company include ML-007C-MA, ML-004, ML-021, ML-009, and other pipeline products.
See More
Previous Close:
$18.01
Open:
$18.28
24h Volume:
197.54K
Relative Volume:
0.78
Market Cap:
$817.85M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+2.24%
1M Performance:
+7.29%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$17.92
$18.89
1-Week Range:
$16.59
$18.89
52-Week Range:
$12.24
$21.55
Maplight Therapeutics Inc Stock (MPLT) Company Profile
Name
Maplight Therapeutics Inc
Sector
Industry
Phone
-
Address
-
Compare MPLT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MPLT
Maplight Therapeutics Inc
|
18.02 | 817.17M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Maplight Therapeutics Inc Stock (MPLT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-21-25 | Initiated | Jefferies | Buy |
| Nov-21-25 | Initiated | Leerink Partners | Outperform |
| Nov-21-25 | Initiated | Morgan Stanley | Overweight |
| Nov-21-25 | Initiated | Stifel | Buy |
Maplight Therapeutics Inc Stock (MPLT) Latest News
USA Herald - USA Herald
MapLight Therapeutics to Participate in Upcoming Investor Conferences - Bitget
Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
MapLight Therapeutics Inc expected to post a loss of 99 cents a shareEarnings Preview - TradingView
MapLight Therapeutics Insider Makes a Major Move With Fresh Stock Sale - TipRanks
Maplight Therapeutics (NASDAQ:MPLT) Director Sells $13,358.40 in Stock - MarketBeat
Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) Director Sells $39,575.85 in Stock - MarketBeat
Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) Director Sells 11,264 Shares of Stock - MarketBeat
Director Malenka sells 14,195 MapLight (MPLT) shares to cover RSU taxes - Stock Titan
MapLight Therapeutics, Inc. Rings the Closing Bell - Nasdaq
Maplight Therapeutics (NASDAQ:MPLT) Shares Gap Up After Insider Buying Activity - Defense World
Insider Buying: George Pavlov Acquires 25,000 Shares of MapLight Therapeutics Inc (MPLT) - GuruFocus
Maplight Therapeutics (NASDAQ:MPLT) Director Acquires $177,171.20 in Stock - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Director Acquires $77,694.54 in Stock - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Director George Pavlov Purchases 10,658 Shares - MarketBeat
MapLight Therapeutics director Pavlov buys shares worth $441k By Investing.com - Investing.com Canada
Malenka Robert C. sells Maplight Therapeutics (MPLT) shares for $220,632 By Investing.com - Investing.com South Africa
Malenka Robert C. sells Maplight Therapeutics (MPLT) shares for $220,632 - Investing.com
Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) Director Sells 12,116 Shares of Stock - MarketBeat
Forbion discloses 7.1% MapLight Therapeutics (MPLT) ownership stake - Stock Titan
Big Insider Shake-Up at MapLight Therapeutics as Directors Make Opposite Moves - TipRanks
Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) Director Sells 6,622 Shares of Stock - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Director Timothy John Garnett Buys 14,124 Shares - MarketBeat
Capital Markets Group Of The Year: Cooley - Law360
Maplight Therapeutics (NASDAQ:MPLT) Shares Gap Down – Time to Sell? - Defense World
Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives $31.00 Average Price Target from Brokerages - Defense World
Maplight Therapeutics (NASDAQ:MPLT) Shares Gap DownTime to Sell? - MarketBeat
Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Malenka sells MapLight (MPLT) shares worth $126,860 By Investing.com - Investing.com Canada
Malenka sells MapLight (MPLT) shares worth $126,860 - Investing.com
Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) Director Sells 7,039 Shares of Stock - MarketBeat
Insider Selling: Maplight Therapeutics (NASDAQ:MPLT) Director Sells $119,743.32 in Stock - Defense World
Malenka sells MapLight Therapeutics (MPLT) stock worth $635,857 - Investing.com India
Malenka sells MapLight Therapeutics (MPLT) stock worth $635,857 By Investing.com - Investing.com Australia
Maplight Therapeutics (NASDAQ:MPLT) Director Robert Malenka Sells 6,524 Shares of Stock - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Director Robert Malenka Sells 21,262 Shares - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Director Sells $119,743.32 in Stock - MarketBeat
MPLT SEC FilingsMapLight Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Maplight Therapeutics (NASDAQ:MPLT) Shares Up 4.8% – Here’s Why - Defense World
Maplight Therapeutics (NASDAQ:MPLT) Stock Price Up 4.8%Still a Buy? - MarketBeat
Biopharma financings pick up in Q4 to cap uneven 2025 recovery - BioWorld MedTech
Maplight Therapeutics (NASDAQ:MPLT) Stock Price Down 7.7%Here's Why - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Stock Price Up 10.5%Time to Buy? - MarketBeat
Maplight Therapeutics Inc Stock (MPLT) Financials Data
There is no financial data for Maplight Therapeutics Inc (MPLT). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):